Brought to you by 
Transcept to become public in merger with Novacea
13 Feb 2009
Executive Summary
Private CNS drug repositioning firm Transcept Pharmaceuticals will reverse merge with publicly traded Novacea (was formerly involved in cancer therapeutics by no longer conducting R&D) in a stock-for-stock transaction.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Transcept to become public in merger with Novacea
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice